类风湿关节炎患者肠道菌群特定肠型预测甲氨蝶呤临床疗效
本研究对145例类风湿关节炎(RA)患者行16S rRNA基因测序,用狄利克雷多项式混合(DMM)聚类鉴定属水平肠型,发现RA患者存在以普雷沃菌属为主的RA E1和以拟杆菌属为主的RA E2两种肠型;仅CD8+ T细胞数量在两组间有显著差异,该结果在中国上海66例RA队列中验证;基于肠型构建的肠道微生物人类指数(EGMI)分类器在另一独立27例RA队列中确认RA E1与后续甲氨蝶呤(MTX)临床应答显著相关。
要点
- RA患者肠道菌群可分为以普雷沃菌属为主的RA E1和以拟杆菌属为主的RA E2两种肠型。
- 仅CD8+ T细胞数量在RA E1与RA E2间有显著差异。
- 基于肠型的EGMI分类器可有效评估MTX临床应答,RA E1与MTX临床应答显著相关。
核心结论
- 基于肠型的肠道微生物人类指数(EGMI)分类器可精准有效识别个体RA患者肠型,并能有效评估MTX临床应答。
研究设计与样本
- 对145例RA患者行16S rRNA基因测序,采用狄利克雷多项式混合(DMM)聚类在属水平鉴定肠型。
- 在中国上海66例RA患者队列中用相同方法评估肠型稳定性。
- 将基于肠型的EGMI分类器应用于另一独立27例RA患者队列,以识别与MTX临床应答相关的因素。
主要发现
- RA患者呈现两种失调菌群模式:RA E1以普雷沃菌属为主,RA E2以拟杆菌属为主。
- 在所有淋巴细胞亚群和细胞因子中,仅CD8+ T细胞数量在RA E1与RA E2间有显著差异,该结果在中国上海RA队列中得到验证。
- 另一独立RA患者队列确认RA E1与后续MTX治疗的临床应答显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The most used drug for the treatment of rheumatoid arthritis (RA) remains methotrexate (MTX). Unfortunately, up to 50% of patients do not achieve a clinically adequate outcome. Here we study whether the gut microbiota patterns can aid in the prediction of MTX efficacy for RA. METHOD: To dissect gut microbiome profiles of RA patients (n = 145), 16S rRNA gene sequencing was performed. Dirichlet multinomial mixture (DMM) clustering was used to identify enterotypes at genus level. The relationships between enterotypes and clinical measures (such as lymphocyte subsets and cytokines detected by flow cytometry) were explored. Then, enterotype stability was evaluated by the stratification of the RA patient cohort (n = 66) in Shanghai, China, using the same method. Finally, the enterotype-based gut microbial human index classifier was applied to another independent RA patient cohort (n = 27) to identify the factors associated with MTX clinical response. RESULTS: Our analysis revealed that the RA patients always displayed two different dysbiotic microbiota patterns: RA E1 comprised predominantly Prevotella and RA E2 comprised predominantly Bacteroides. Among all of the lymphocyte subsets and cytokines, only the number of CD8+ T cells showed a significant difference between RA E1 and RA E2. These results were validated in the RA patient cohort in Shanghai, China. Significant associations of RA E1 with clinical response to subsequent MTX treatment were confirmed by another independent RA patient cohort. CONCLUSION: Together, the enterotype-based gut microbial human index (EGMI) classifier was useful to precisely and effectively identify enterotypes of individual RA patients, which could effectively evaluate MTX clinical responses.
引用
- Qiao J, Zhang SX, Chang MJ, et al. Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 35946529. doi:10.1093/rheumatology/keac458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。